Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Frontotemporal dementia

Neurology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Abrupt behavioural change, fluctuating attention, fever, new focal deficit, seizure, severe self-neglect, violence, suicidality or inability to meet basic needs is not safely attributed to frontotemporal dementia without urgent assessment for delirium, neurological disease and immediate safeguarding risk.

Synopsis

Recognise behavioural and language-led frontotemporal degeneration, distinguish it from psychiatric and Alzheimer presentations, and coordinate genetic, communication, safeguarding and multidisciplinary care.

  • Frontotemporal dementia often begins before 65 and presents with progressive personality, behaviour, executive or language change while episodic memory and visuospatial skills can be relatively preserved early.
  • Behavioural-variant FTD features early disinhibition, apathy, loss of empathy, stereotyped or compulsive behaviour, hyperorality and executive dysfunction.
  • Primary progressive aphasia may be semantic, with loss of word and object meaning, or non-fluent or agrammatic, with effortful speech and impaired grammar or speech planning.
  • Obtain collateral history because reduced insight is common and a clinic conversation can underestimate home, financial, sexual, dietary or occupational consequences.
  • MRI may show frontal or anterior temporal atrophy, often asymmetric, but diagnosis integrates progression, phenotype, cognitive testing and exclusion of mimics rather than a scan alone.
  • Ask about motor neurone disease, parkinsonism and a three-generation family history; a substantial minority of FTD is genetic and counselling should precede predictive testing.
  • NICE advises not offering acetylcholinesterase inhibitors or memantine for frontotemporal dementia because these Alzheimer medicines do not treat its core pathology.
  • Non-drug care should adapt the environment, preserve routine, support communication, manage eating and risk, and protect carers from escalating burden.
  • SSRIs or trazodone are sometimes used off label for selected behaviours, but evidence is limited; define a target, discuss uncertainty and stop when no meaningful benefit occurs.

Key red flags

Motor overlap

Fasciculation, weakness, spasticity, dysphagia, parkinsonism, apraxia or impaired vertical eye movement may reveal overlap with motor neurone or atypical parkinsonian degeneration.

Acute mimic

Hours-to-days change, impaired attention, altered consciousness, infection, medication toxicity or a new lesion indicates delirium or another emergency rather than uncomplicated neurodegeneration.

Investigation priorities

01
Collateral history and functional inventoryFirst step

Establish progressive change in social cognition, language, executive function and everyday risk beyond the clinic snapshot.

Management branches

RecognitionTurn behaviour into a neurological history

Personality, conduct or language has changed progressively in adult life.

  1. Obtain private and joint collateral examples of timing, progression, empathy, inhibition, routines, eating, language, finances, driving and occupational performance.
  2. Assess attention, mood, psychosis, substance use, sleep and medicines, separating gradual network decline from delirium, primary psychiatric illness and situational conflict.
  3. Examine cognition, language, eye movements, parkinsonism and upper and lower motor neurone signs, and arrange standard blood and structural imaging assessment.
  4. Refer to a cognitive-neurology or young-onset dementia service for neuropsychology, biomarker decisions and a formulation shared with the family.

Key medicines

Selective serotonin reuptake inhibitorIf used off label, start the chosen SSRI at a low standard adult dose and titrate cautiously to a predefined behavioural target.Review hyponatraemia, bleeding, falls, activation and interactions; avoid using sedation as convenience, document uncertainty and stop when target behaviour does not improve.
TrazodoneSpecialists may use a low evening dose and titrate within BNF limits when agitation or behavioural symptoms justify an off-label trial.Sedation, postural hypotension, falls, priapism and serotonergic interactions matter; an individual target and short review interval are essential.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG97 dementia assessment and managementSubtype diagnosis, multidisciplinary support and medicines not recommended in FTD.
  • NICE NG127 suspected neurological conditionsReferral and urgent-mimic principles for cognitive and neurological change.
  • Genomics Education frontotemporal dementiaNHS genomic indications, genes and family counselling context.
  • Mental Capacity Act code of practiceDecision-specific capacity and lawful future planning.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom